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Novel 2-(4-aminophenyl)benzothiazoles possess highly selective, potent antitumour properties in vitro and in vivo. They induce
and are biotransformed by cytochrome P450 (CYP) 1A1 to putative active as well as inactive metabolites. Metabolic
inactivation of the molecule has been thwarted by isosteric replacement of hydrogen with ﬂuorine atoms at positions around
the benzothiazole nucleus. The lipophilicity of these compounds presents limitations for drug formulation and bioavailability.
To overcome this problem, water soluble prodrugs have been synthesised by conjugation of alanyl- and lysyl-amide
hydrochloride salts to the exocyclic primary amine function of 2-(4-aminophenyl)benzothiazoles. The prodrugs retain
selectivity with signiﬁcant in vitro growth inhibitory potency against the same sensitive cell lines as their parent amine, but are
inactive against cell lines inherently resistant to 2-(4-aminophenyl)benzothiazoles. Alanyl and lysyl prodrugs rapidly and
quantitatively revert to their parent amine in sensitive and insensitive cell lines in vitro. Liberated parent compounds are
sequestered and metabolised by sensitive cells only; similarly, CYP1A1 activity and protein expression are selectively induced
in sensitive carcinoma cells. Amino acid prodrugs meet the criteria of aqueous solubility, chemical stability and quantitative
reversion to parent molecule, and thus are suitable for in vivo preclinical evaluation.
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Novel 2-(4-aminophenyl)benzothiazoles possess remarkable and
intriguing antitumour properties (Shi et al, 1996; Bradshaw et al,
1998a) representing a mechanistic class distinct from clinically used
chemotherapeutic agents. Consistently, they are active against only
a speciﬁc subset of human cancer cell lines in the National Cancer
Institute (NCI) in vitro anticancer drug screen, producing mean
graph patterns that are highly characteristic of this class of
compounds only. Moreover, growth inhibition in vitro is charac-
terised by a unique biphasic dose-response relationship
(Bradshaw et al, 1998a,b). In vivo, 2-(4-amino-3-methylphenyl)-
benzothiazole compound 1 outperformed the 3'-halogeno
counterparts in breast, colon and ovarian xenograft studies.
Compound 1 is efﬁciently sequestered by sensitive cell lines (e.g.
breast MCF-7, MDA-468; renal TK-10) (Chua et al, 1999; Kashiya-
ma et al, 1999). CYP1A1 mRNA (Hose et al, 2001; Monks et al,
2001) activity and protein expression (Chua et al, 2000) are
induced exclusively in sensitive cell lines. Covalent binding,
detected between compound 1 and recombinant CYP1A1, requires
metabolism and is signiﬁcantly reduced by glutathione (Chua et al,
2000). This suggests that an electrophilic, reactive intermediate
species is formed. The C-6 oxidation biotransformation product,
liberated into nutrient media, however, is devoid of antitumour
activity (Kashiyama et al, 1999). Moreover, this metabolite antago-
nises cellular uptake of compound 1, covalent binding between
CYP1A1 and compound 1, CYP1A1 activity and growth inhibition
induced by compound 1. In addition, hydroxy derivatives of
compound 1 possess mitogenic properties at mM concentrations
(Hutchinson et al, 2001). In contrast, insensitive cell lines (e.g.
breast MDA-MB-435; renal A498, CAKI-1; prostate PC-3) neither
retain nor metabolise compound 1 (Kashiyama et al, 1999).
Fluorinated analogues of 2-(4-aminophenyl)benzothiazoles have
been synthesised which successfully block C-oxidation (Hutchinson
et al, 2001). 2-(4-Amino-3-methylphenyl)-5-ﬂuorobenzothiazole
(compound 2) is the favoured analogue for clinical consideration
possessing enhanced efﬁcacy in vitro and superior potency in vivo
against human breast and ovarian tumour xenografts implanted
in nude mice. 2-(4-Aminophenyl)benzothiazoles, which are synthe-
tically accessible, small and lipophilic pose a pharmaceutical
challenge, as aqueous i.v. formulations would be desired to mini-
mise the possibility of ﬁrst pass deactivating metabolism and
improve drug bioavailability.
Amino acid conjugation may be utilised to enhance the
aqueous solubility of amine or alcohol drugs (as amide or ester
prodrugs respectively). The primary aromatic amine, dapsone,
has been derivatised as amino acid amides fulﬁlling the criteria
for a suitable prodrug–water solubility, chemical stability and
rapid, quantitative bioreversion to the parent moiety (Pochopin
et al, 1995). The exocyclic primary amine function of 2-(4-
amino-3-methylphenyl)benzothiazoles has been successfully conju-
gated to alanine and lysine residues as the mono- and
dihydrochloride salts respectively (Hutchinson et al, 2002); such
structural manipulation converts lipophilic benzothiazoles into
water soluble prodrugs (Figure 1). Herein, reversion of prodrugs
to parent molecule and selective antitumour activity in vitro has
been described. In addition, we demonstrate that interaction with
the putative molecular target of this class of agent, CYP1A1, has
not been compromised.
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Growth inhibitory assays
Prodrugs were prepared as 10 mM top stocks, dissolved in
dimethylsulphoxide (DMSO) or sterile ddH2O, and stored at
48C, protected from light for a maximum period of 4 weeks.
MCF-7 (ER+) and MDA 468 (ER7) human derived breast carci-
noma cells, cultivated at 378C in an atmosphere of 5% CO2 in
RPMI 1640 medium supplemented with 2 mML -glutamine and
10% foetal calf serum, were routinely subcultured twice weekly
to maintain continuous logarithmic growth. Cells were seeded
into 96-well microtiter plates at a density of 5610
3 per well
and allowed 24 h to adhere before drugs were introduced (ﬁnal
concentration 0.1 nM–100 mM, n=8). Serial drug dilutions were
prepared in medium immediately prior to each assay. Viable cell
masses at the time of drug addition (time-zero), and following
72 h drug exposure were determined by cell-mediated 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
reduction. MTT was added to each well (ﬁnal concentration
400 mgm l
71) and plates were incubated at 378C for 4 h to allow
reduction of MTT by viable cell dehydrogenases to an insoluble
formazan product. Well supernatants were aspirated and cellular
formazan solubilised by addition of DMSO:glycine buffer
(pH 10.5) (4:1). Cell growth as well as drug activity were deter-
mined by measuring absorbance at 550 nm using an Anthos
Labtec systems plate reader.
NCI in vitro cytotoxicity assays
Cell culture and drug application procedures have been described
previously (Boyd and Paull, 1995). Brieﬂy, cell lines were inocu-
lated into a series of 96-well microtiter plates, with varied
seeding densities depending on growth characteristics of each cell
line. Following a 24 h drug free incubation, test agents were added
at ﬁve 10-fold dilutions with a maximum concentration of 100 mM.
Cellular protein levels were determined after 48 h drug exposure by
sulphorhodamine B colorimetry.
Metabolism studies
MCF-7 cells were seeded into 25 ml ﬂasks at appropriate densities
(5610
5–5610
6). After 24 h, medium was changed and drug
introduced at a ﬁnal concentration of 10 mM. Media samples,
collected from ﬂasks at time zero and 24 h intervals, were mixed
with 1.5-fold volumes of high performance liquid chromatography
(HPLC) grade acetonitrile to precipitate protein and centrifuged
at 14000 g for 5 min. Supernatants (600 ml) were mixed with
400 ml 10% acetonitrile in 1% acetic acid and analysed by HPLC.
The system consisted of Beckman System Gold equipment
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Figure 1 Structures of 2-(4-aminophenyl)benzothiazoles and their amino acid prodrugs.
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UV detector 168). Separation of parent compounds and biotrans-
formation products was effected at room temperature on a
Phenomenex Aqua C18 reversed-phase column (15064.6 mm).
The mobile phase was formed by increasing, then decreasing the
acetonitrile concentration in 1% acetic acid over 20 min by
mixing two solutions: acetonitrile-water-acetic acid (10:90:1,
vv
71) and acetonitrile-water-acetic acid (80:20:1 v v
71) and
delivered at a ﬂow rate of 1 ml min
71. Compounds were detected
at 324 nm.
Western blot protocol
Whole cell lysates were prepared for examination of CYP1A1
protein expression from untreated MCF-7, IGROV-1 and HCT
116 cultures and following exposure of cells to compounds 1,
2, 2a, 2b, 3, 3a, 3b, 4, 4a and 4b. Following protein determi-
nation (n=3, Bradford, 1976) and addition of sample buffer,
samples were boiled at 958C for 5 min and solubilised proteins
(50 mg) were separated by sodium dodecyl sulphate (SDS) poly-
acrylamide gel (10%) electrophoresis. Proteins were
electroblotted to polyvinylidene diﬂuoride (PVDF) membranes
and probed for CYP1A1 protein with polyclonal antiserum
speciﬁc for human CYP1A1/1A2 (Gentest Corporation). Second-
ary antibody was conjugated to alkaline phosphatase, and
CYP1A1 was detected following brief (510 min) incubation
with bromochloroindolyl phosphate and nitro-blue tetrazolium
in alkaline phosphatase buffer. Molecular weight markers and
a positive control of recombinant CYP1A1 (Gentest Corpora-
tion), included in all blots, conﬁrmed detection of 52 kDa
CYP1A1 protein.
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Figure 2 Uptake and conversion of 10 mM compounds 1a to 1 in: (A)
inherently insensitive A498 renal cells and (B) sensitive ER+ T47D breast
cells. Compound 1a is rapidly and efﬁciently hydrolysed by both cell lines.
Only sensitive cells (B) sequester regenerated compound 1.
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Figure 3 Depletion of (A) compound 2a,( B) compound 3a and (C)
compound 4a (10 mM) from nutrient media supporting MCF-7 growth,
conversion of prodrugs to the corresponding parent amine and further
metabolism of compounds 3 and 4 only by MCF-7 cells (B and C).
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(EROD activity)
A sensitive and rapid ﬂuorometric assay was used to measure
EROD activity (Burke et al, 1994). Incubation mixtures (total
1 ml) consisted of 100 mM Tris-HCl (pH 7.4), 50 mM MgCl2,
100 mM 7-ethoxyresoruﬁn and 100 ml cell homogenate. Homoge-
nates were prepared following treatment of cells for 24 h with
compounds 1, 2, 2a, 2b, 3, 3a, 3b, 4, 4a and 4b or vehicle alone
and protein content determined (n=3). Thus induction of
ethoxy-resoruﬁn O-deethylation by agents under study, catalysed
by CYP1A1 activity, could be determined. Alternatively, micro-
somes expressing recombinant CYP1A1 (0.1 mg ml
71) provided
the enzyme source for EROD catalysis, in the presence or absence
of drug, in order to determine inhibition of CYP1A1 activity by
compounds 1, 2, 2a, 2b, 3, 3a, 3b, 4, 4a and 4b. Incubation
mixtures were pre-incubated for 5 min at 378C before initiation
of reaction by addition of NADPH (500 mM). Following further
incubations at 378C (30 min for cell homogenates, 15 min for
CYP1A1 microsomes), reactions were terminated by addition of
3 ml ice-cold acetonitrile. Reaction mixtures were centrifuged
(1400 r.p.m., 10 min) before analyses of supernatants. Fluorescence
was read on a Perkin-Elmer LS-5 luminescence spectrometer (exci-
tation, 530 nm; emission 585 nm). Estimation of resoruﬁn reaction
product (pmoles mg
71 protein, pmoles 100 mg
71 microsomes), as
a measure of CYP1A1 activity, was determined following perfor-
mance of a resoruﬁn standard curve.
RESULTS
Prodrug uptake and conversion to parent amine
Uptake and metabolism of compounds 1a and 1b were examined
in sensitive breast (MCF-7 and T47D) and insensitive renal
(A498) cells using HPLC conditions which allow simultaneous
detection of prodrug, parent amine and metabolites. When incu-
bated at 0.1, 1 or 10 mM over 7 days at 378C, the lysyl-amide
compound 1a was most readily removed from the media support-
ing MCF-7 and T47D cells (Figure 2). The decline of each prodrug
in media was accompanied by the appearance of compound 1.
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Figure 4 Mean GI50 graph demonstrating the selective nature of growth inhibition by (A) compound 2 and (B) compound 2b in the NCI in vitro panel of
human derived cancer cell lines. Cells were exposed to drug for 48 h before viability was determined using the sulforhodamine B assay. Display of data
utilises the mean graph format where the average GI50 concentration is plotted on the centre line. Using a log scale, the sensitivity or resistance of a particular
cell line is represented by deﬂections to the right or left, respectively, from the mean.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1348–1354Media levels of regenerated compound 1 reached a peak at day 3,
thereafter declining as oxidative metabolism by MCF-7 and T47D
sensitive cells yielded its inactive 6-hydroxy metabolite. In contrast,
negligible net removal of efﬂuxed compound 1 occurred from
media supporting the growth of inherently resistant A498 cells,
which fail to sequester and metabolise 2-(4-aminophenyl)ben-
zothiazoles (Kashiyama et al, 1999). Thus, compound 1,
regenerated from the amide prodrugs accumulated harmlessly in
the media of A498 cells over the 7 day incubation period.
Amino acid prodrugs of compounds 2, 3 and 4 were stable in
medium alone at 378C47 days: detection of parent drug during
this time was negligible. Uptake and metabolism of compounds
2a, 2b, 3a, 3b, 4a and 4b (10 mM) by MCF-7 cells were examined;
conditions for HPLC analysis allowed detection of prodrug, parent
compound and metabolites. All alanyl- and lysyl-amide prodrugs
were rapidly depleted from nutrient media in the presence of cells
and conversion of prodrugs to parent amines was apparent after
24 h. Release of compound 2 into nutrient medium was signiﬁcant
after 24 h and continued to increase throughout the 7 day period.
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Table 1 Retention of biological activity following conjugation of alanyl
and lysyl residues to 2-(4-amino-3-methylphenyl)benzothiazole com-
pounds 1, 2, 3 and 4
Induction Microsomal
GI50 GI50 EROD activity: CYP1A1
MCF-7 MDA 468 nM resoruﬁn EROD activity
Compound (nM)( n M)m g
71 protein (% control)
1 50.1
a 50.1
a 17.58 22.58
1a 0.32 39.9 nd nd
1b 41.6 67.1 nd nd
2 50.1 50.1 36.64 30.40
2a 5.8 37.7 28.37 40.59
2b 39.1 57.7 35.56 38.48
b
3 0.65
a 0.73
a 32.60 36.38
3a 43.5 296.6 20.40 28.90
3b 147.1 328.0 19.88 46.97
4 50.1
a 3.55
a 32.02 43.15
4a 33.0 219.9 17.09 41.92
4b 30.7 301.7 20.04 54.94
(1) Inhibition of ER+ MCF-7 and ER7 MDA 468 human breast carcinoma cell
growth. Cells were treated with compound for 3 days (n=8) before viability was
assessed by MTT assay. Experiments were performed three times and representa-
tive mean values shown.
aSigniﬁes a biphasic dose response relationship. (2)
Induction of EROD activity in lysates of MCF-7 cells treated with compounds
(1 mM, 24 h). Negligible activity was detected in control, untreated cell lysates. Means
of three experiments are shown, s.d. 510%. (3) Inhibition of recombinant CYP1A1
activity by 30 mM agent. Incubates containing no drug represent 100% activity. Means
of three experiments are shown, s.d. 510%.
bThis data is represented graphically in
Figure 5B. nd=experiments not performed.
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Figure 5 Western Blot detection of CYP1A1 protein induced in lysates
of (A) MCF-7 cells exposed to compounds 1, 2, 3, 4, 2a, 2b, 3a, 3b, 4a
and 4b (1 mM, 24 h). CYP1A1 expression was not detected constitutively
in lysates of untreated MCF-7 or (B) HCT 116 cells and not induced in
HCT 116 cells exposed to compounds 1, 2, 3 or 2b. For each sample,
50 mg total protein was loaded onto the gel.
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Figure 6 (A) EROD activity in homogenates of IGROV-1 cells treated
with concentrations of compound 2b for 24 h. Mean values of three ex-
periments are shown; bars, s.d. (B) Inhibition of CYP1A1 microsomal
EROD activity by compound 2b. Resoruﬁn product was measured after
coincubation of CYP1A1 microsomes with compount 2b for 15 min at
378C. Mean values of three experiments are shown; bars, s.d.
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British Journal of Cancer (2002) 86(8), 1348–1354 ã 2002 Cancer Research UKNo biotransformation products could be detected (Figure 3A). In
contrast, emergence of an oxidative metabolite accompanied detec-
tion of compounds 3 and 4 (days 1–7, Figure 3B,C).
In vitro cytotoxicity
In the NCI panel of human-derived carcinoma cell lines, tested
amino acid salts of compounds 1, 2 and 3 retained the selective
growth inhibitory properties of their parent amines; mean graphs
demonstrated activity against certain ovarian, renal and breast cell
lines following standard 48 h exposure (e.g. Figure 4). However, as
expected considering the prodrug nature of compound 2b, follow-
ing 48 h exposure, potency at the GI50 level in sensitive cell lines
was reduced. Data obtained following examination of activity of
amino acid salts of compounds 1, 2, 3 and 4 in MCF-7 and
MDA 468 breast cancer cells corroborates this observation: typi-
cally, after 72 h exposure, GI50 values were two orders of
magnitude greater than the parent amine (Table 1). However,
neither alanyl nor lysyl prodrugs evoked the biphasic dose response
characteristic of sensitive cell lines exposed to non-conjugated
parent amines compounds 1, 3 or 4.
Mechanism of action studies
Figure 5 demonstrates selective induction of CYP1A1 protein
expression in lysates of MCF-7 cells treated with benzothiazole
prodrugs and their parent amines (1 mM, 24 h). No CYP1A1 was
detected in lysates of HCT 116 or untreated MCF-7 cells. In addi-
tion, expression of CYP1A1 protein was clearly observed in lysates
of IGROV-1 cells after exposure to concentrations of compound 2b
between 10 nM and 10 mM (24 h, result not shown). Similarly, only
lysates of sensitive cells exposed to prodrugs effected deethylation
of ethoxyresoruﬁn, indicative of CYP1A1 activity (Table 1). Figure
6A demonstrates the biphasic dose response relationship between
CYP1A1-catalysed conversion of ethoxyresoruﬁn to resoruﬁn and
compound 2b concentration in lysates of IGROV-1 cells exposed
to this agent for 24 h. Maximum induction of EROD activity
followed treatment of cells with 1 mM compound 2b. It has been
speculated that these agents are metabolised by CYP1A1 to a reac-
tive intermediate that covalently binds to, and then inactivates the
enzyme; the activity of CYP1A1 microsomes was irreversibly inhib-
ited by compound 1 (Chua et al, 2000). Indeed, signiﬁcant
inhibition of CYP1A1 microsomal EROD activity was monitored
when incubates included compounds 1, 2, 2a, 2b, 3, 3a, 3b, 4,
4a, 4b (Table 1, Figure 6B).
DISCUSSION
Data have been presented describing the in vitro biological proper-
ties of alanyl and lysyl amide derivatives of 2-(4-amino-3-
methylphenyl)benzothiazoles. Prodrugs are rapidly depleted from
nutrient media, generating their parent species in the presence of
cells (Figures 2 and 3). In the absence of cells, no spontaneous
hydrolysis of the amide bond occurs to release the amine from
its amino acid salt. The cleavage of amino acid amides may be
catalysed by ubiquitously expressed aminopeptidases, but subse-
quent bioactivating steps, essential for the mechanism of action
of aminophenylbenzothiazoles, take place selectively in sensitive cell
lines (e.g. Figure 5). Compounds 1a and 1b were stable when incu-
bated at 378C with human plasma; speciﬁcally, no free amine was
detected. Amino acid amide stability, assessed in aqueous solution
over a pH range of 4–9, was found to be pH dependent with more
acidic pH favouring greater stability (Hutchinson et al, 2002).
The selective depletion of amine (e.g. compound 1, Figure 2b)
from nutrient media in vitro, and accumulation in sensitive cells
only has been reported previously (Kashiyama et al, 1999; Chua
et al, 2000).
The remarkably potent and selective antitumour activity charac-
teristic of this class of agent is retained; total growth inhibition
(TGI) and cytocidal effects (LC50) were elicited by nM concentra-
tions following amino acid conjugation coupled with monoﬂuoro
substitution. In vitro, prodrug compound 2b exhibits a superior
antitumour proﬁle. In vivo, plasma concentrations of compound
2, regenerated from lysylamide prodrug compound 2b, sufﬁcient
to elicit cytocidal activity against human mammary carcinoma cells
persist 46 h (Bradshaw et al, 2002). Indeed, compound 2b
suppresses signiﬁcantly the growth of breast and ovarian xenografts
in vivo.
Planar, hydrophobic 2-(4-aminophenyl)benzothiazoles fulﬁl
structural requirements for binding to the aryl hydrocarbon recep-
tor (AhR), and are potent AhR agonists (Loaiza-Perez et al, 2002).
Subsequent induction of CYP1A1 mRNA (Hose et al, 2001; Monks
et al, 2001) activity and protein expression (Chua et al, 2000;
Hutchinson et al, 2001) only in cell lines sensitive to the growth
inhibitory properties of 2-(4-amino-3-methylphenyl)benzothiazoles
has been reported. That the role of CYP1A1 as a putative target for
the mechanism of action of this class of compound was not
compromised following prodrug modiﬁcation of the 2-(4-amino-
phenyl)benzothiazole structure has been veriﬁed (Table 1, Figures
5 and 6). Induction of CYP1A1 protein expression and EROD
activity in lysates of sensitive MCF-7 breast, IGROV-1 ovarian cells
was observed following exposure to prodrugs. Lysates of insensitive
HCT 116 cells treated with prodrugs neither expressed CYP1A1
protein nor effected ethoxyresoruﬁn O-deethylation.
Induction of CYP1A1 activity and protein expression probably
leads to generation of a reactive electrophilic species and
benzothiazole-derived covalent binding to CYP1A1, resulting in
enzyme inactivation (Chua et al, 2000). We have established that
at prodrug compound 2b concentrations 41 mM, EROD activity,
induced in lysates of treated sensitive cells, begins to decline
(Figure 6A). Moreover, mM prodrug concentrations inhibit micro-
somal CYP1A1 activity (Figure 6B), substantiating the thesis that
these agents are inducers, substrates and suicide inhibitors of
CYP1A1. Generation of a CYP1A1-dependent reactive electrophilic
species preceeds detection of DNA adducts (Stevens et al, 2001),
and ultimately cell death.
In conclusion, alanyl- and lysyl-amide prodrugs of 2-(4-amino-
3-methylphenyl)benzothiazoles undergo reversion to their parent
amine. In vitro efﬁcacy and selectivity are retained. Stark antitu-
mour selectivity can be rationalised, and involvement of a crucial
molecular target of this class of agent demonstrated. In addition,
chemical stability and aqueous solubility is exhibited rendering
these synthetically accessible prodrugs suitable for further preclini-
cal development.
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